Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Sei Investments Co.

Sei Investments Co. decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 30.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 98,338 shares of the company’s stock after selling 43,166 shares during the quarter. Sei Investments Co.’s holdings in Medpace were worth $32,671,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of MEDP. R Squared Ltd bought a new stake in shares of Medpace during the 4th quarter worth $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Medpace in the 4th quarter valued at $31,000. Stone House Investment Management LLC acquired a new position in shares of Medpace in the 3rd quarter valued at $33,000. Jones Financial Companies Lllp increased its stake in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares in the last quarter. Finally, Lindbrook Capital LLC raised its holdings in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after buying an additional 29 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 1.8 %

NASDAQ MEDP opened at $324.51 on Wednesday. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77. The firm’s fifty day simple moving average is $337.16 and its 200-day simple moving average is $339.57. The company has a market capitalization of $9.89 billion, a PE ratio of 25.69, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

MEDP has been the topic of several analyst reports. Robert W. Baird lifted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday. Finally, Leerink Partners initiated coverage on shares of Medpace in a research note on Monday. They set a “market perform” rating and a $330.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.